2023年1月26日 · Oral roflumilast was efficacious and safe in treating moderate-to-severe plaque psoriasis over 24 weeks. With generic versions available, this drug may represent an inexpensive and convenient alternative to established systemic psoriasis treatments.

Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor used for the treatment of COPD and plaque psoriasis. Topical roflumilast 0.3% cream (Zorvye™) was approved by the FDA in 2022 for the treatment of plaque psoriasis in patients aged 12 years and older.

Roflumilast cream 0.3% has been studied in patients with chronic plaque psoriasis, including intertriginous areas, in patients ≥2 years of age. Results of this long-term trial indicate once-daily roflumilast was well tolerated and effectiveness was maintained up to 64 weeks.

Roflumilast is effective and safe for the treatment of plaque psoriasis and intertriginous psoriasis. Future trials should compare its efficacy and tolerability with that of the older, clinically established topical corticosteroids.

In patients with plaque psoriasis, topical roflumilast 0.3% led to higher achievement of clinical milestones compared with vehicle, including increased rates of IGA or body-IGA success, intertriginous-IGA success, and significant improvements in PASI, with a favorable safety profile.

2023年3月20日 · New late-breaking data showed that oral roflumilast treatment was both safe and efficacious against psoriasis, making it a potentially less expensive and convenient treatment alternative.

2024年4月2日 · Once-daily roflumilast cream 0.3% in adults with chronic plaque psoriasis was well-tolerated and had good efficacy up to 64 weeks in an open-label phase 2 trial, suggesting it is suitable for...

Roflumilast cream 0.3% is a once daily phosphodiesterase-4 inhibitor that was recently approved by the FDA for the treatment of plaque psoriasis in adolescents and adults. It is indicated for use on all body surfaces including intertriginous areas.

Plaque psoriasis is a multisystem inflammatory disease that affects children and adults. Skin lesions are the most prominent manifestation, appearing as localized or widespread red plaques with silvery scale.

2020年7月16日 · Roflumilast cream administered once daily to affected areas of psoriasis was superior to vehicle cream in leading to a state of clear or almost clear at 6 weeks. Longer and larger trials are needed to determine the durability and safety of roflumilast in psoriasis.